Vironexis Biotherapeutics, Inc.

Vironexis Biotherapeutics is a US-based company focused on developing innovative AAV-delivered T-cell immuno-gene therapies for cancer treatment, specifically targeting blood-based cancers and solid tumors. Founded in 2021, Vironexis Biotherapeutics specializes in AAV-delivered therapies aimed at revolutionizing cancer treatment. The company has secured USD 26 mn in Seed funding in October 2022, led by Drive Capital and Future Ventures. The founder, Timothy Cripe, previously established other ventures that underscore his expertise in biotech.

Vironexis does not have any parent companies or subsidiaries, and its headquarters is located in the United States. Vironexis Biotherapeutics specializes in pioneering AAV-delivered T-cell immuno-gene therapies designed to transform cancer treatment. The core offering is their AAV Gene Therapy Platform, TransJoin™, which allows for the delivery of engineered transgenes to T cells through a one-time infusion, eliminating the need for pre-treatment and custom manufacturing. Their therapies primarily serve patients with blood-based cancers and aim to prevent solid tumor metastasis.

The company targets markets in North America, Europe, and select regions in Asia. Vironexis Biotherapeutics generates revenue through strategic partnerships and collaborations with healthcare institutions, pharmaceutical companies, and research organizations. Their revenue model focuses on B2B transactions, involving licensing agreements, milestone payments, and revenue-sharing arrangements, particularly through their flagship product, the TransJoin™ AAV Gene Therapy, which targets tumors and aims for a sustained immune response. Pricing structures for these therapies are customized based on client agreements and development scopes.

Following the recent Seed funding of USD 26 mn raised in October 2022, Vironexis Biotherapeutics plans to utilize these resources to advance its oncology programs into clinical trials. The company is focusing on expanding its product pipeline for innovative cancer treatments and aims to enter additional markets in Europe and Asia by 2025, in response to the growing demand for effective cancer therapies.